69 related articles for article (PubMed ID: 20832391)
1. Akti-1/2, an allosteric inhibitor of Akt 1 and 2, efficiently inhibits CaMKIα activity and aryl hydrocarbon receptor pathway.
Gilot D; Giudicelli F; Lagadic-Gossmann D; Fardel O
Chem Biol Interact; 2010 Dec; 188(3):546-52. PubMed ID: 20832391
[TBL] [Abstract][Full Text] [Related]
2. Activation of the aryl hydrocarbon receptor by the calcium/calmodulin-dependent protein kinase kinase inhibitor 7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid (STO-609).
Monteiro P; Gilot D; Langouet S; Fardel O
Drug Metab Dispos; 2008 Dec; 36(12):2556-63. PubMed ID: 18755850
[TBL] [Abstract][Full Text] [Related]
3. Dioxin-mediated up-regulation of aryl hydrocarbon receptor target genes is dependent on the calcium/calmodulin/CaMKIalpha pathway.
Monteiro P; Gilot D; Le Ferrec E; Rauch C; Lagadic-Gossmann D; Fardel O
Mol Pharmacol; 2008 Mar; 73(3):769-77. PubMed ID: 18089838
[TBL] [Abstract][Full Text] [Related]
4. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes.
Andrieux L; Langouët S; Fautrel A; Ezan F; Krauser JA; Savouret JF; Guengerich FP; Baffet G; Guillouzo A
Mol Pharmacol; 2004 Apr; 65(4):934-43. PubMed ID: 15044623
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes.
Berggreen C; Gormand A; Omar B; Degerman E; Göransson O
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E635-46. PubMed ID: 19158325
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of CYP1A1 by rutaecarpine is dependent on aryl hydrocarbon receptor and calcium.
Han EH; Kim HG; Im JH; Jeong TC; Jeong HG
Toxicology; 2009 Dec; 266(1-3):38-47. PubMed ID: 19853001
[TBL] [Abstract][Full Text] [Related]
7. Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor.
Kim SH; Henry EC; Kim DK; Kim YH; Shin KJ; Han MS; Lee TG; Kang JK; Gasiewicz TA; Ryu SH; Suh PG
Mol Pharmacol; 2006 Jun; 69(6):1871-8. PubMed ID: 16540597
[TBL] [Abstract][Full Text] [Related]
8. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
van der Merwe JQ; Moreau F; MacNaughton WK
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
[TBL] [Abstract][Full Text] [Related]
9. BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.
Carlson CB; Mashock MJ; Bi K
J Biomol Screen; 2010 Mar; 15(3):327-34. PubMed ID: 20145103
[TBL] [Abstract][Full Text] [Related]
10. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Granville CA; Memmott RM; Gills JJ; Dennis PA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
[TBL] [Abstract][Full Text] [Related]
12. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
13. Microtubules-interfering agents restrict aryl hydrocarbon receptor-mediated CYP1A2 induction in primary cultures of human hepatocytes via c-jun-N-terminal kinase and glucocorticoid receptor.
Vrzal R; Daujat-Chavanieu M; Pascussi JM; Ulrichova J; Maurel P; Dvorak Z
Eur J Pharmacol; 2008 Mar; 581(3):244-54. PubMed ID: 18177856
[TBL] [Abstract][Full Text] [Related]
14. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro.
Toulany M; Dittmann K; Fehrenbacher B; Schaller M; Baumann M; Rodemann HP
DNA Repair (Amst); 2008 Oct; 7(10):1746-56. PubMed ID: 18678286
[TBL] [Abstract][Full Text] [Related]
15. RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity.
Gilot D; Le Meur N; Giudicelli F; Le Vée M; Lagadic-Gossmann D; Théret N; Fardel O
PLoS One; 2011 Mar; 6(3):e18261. PubMed ID: 21479225
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Layton ME; Bilodeau MT
Curr Cancer Drug Targets; 2008 Feb; 8(1):7-18. PubMed ID: 18288939
[TBL] [Abstract][Full Text] [Related]
17. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
18. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cherrin C; Haskell K; Howell B; Jones R; Leander K; Robinson R; Watkins A; Bilodeau M; Hoffman J; Sanderson P; Hartman G; Mahan E; Prueksaritanont T; Jiang G; She QB; Rosen N; Sepp-Lorenzino L; Defeo-Jones D; Huber HE
Cancer Biol Ther; 2010 Apr; 9(7):493-503. PubMed ID: 20139722
[TBL] [Abstract][Full Text] [Related]
19. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a chemical affinity probe targeting Akt kinases.
Pachl F; Plattner P; Ruprecht B; Médard G; Sewald N; Kuster B
J Proteome Res; 2013 Aug; 12(8):3792-800. PubMed ID: 23795919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
